Treatment of Pneumonia in Long-Term Care Facilities

Initial Assessment and Risk Stratification

The American College of Cardiology is not mentioned, however, the British Thoracic Society recommends that for pneumonia in long-term care residents, oral amoxicillin-clavulanate is the preferred first-line antibiotic, with oral respiratory fluoroquinolones as an alternative, particularly when beta-lactamase producing organisms or atypical pathogens are suspected, and most long-term care residents with pneumonia can be adequately treated with oral antibiotics and do not require hospitalization 1, 2
Key vital signs that suggest the need for hospitalization or parenteral therapy include a pulse greater than 120 beats per minute, respiratory rate greater than 30 per minute, systolic blood pressure less than 90 mmHg, and oxygen saturation requiring supplemental oxygen, according to the British Thoracic Society 2

The microbiology of pneumonia in long-term care facilities differs significantly from community-acquired pneumonia, with Streptococcus pneumoniae remaining important, and gram-negative bacteria and Staphylococcus aureus being substantially more common than in community settings, according to the Infectious Diseases Society of America 3
Atypical pathogens like Legionella and Mycoplasma are infrequently detected in this population, as stated by the Infectious Diseases Society of America 3

The British Thoracic Society recommends amoxicillin-clavulanate as appropriate for long-term care facility pneumonia, particularly when beta-lactamase producing organisms are a concern, and second-generation cephalosporins, such as cefuroxime, are also acceptable options 1, 4
Respiratory fluoroquinolones, such as levofloxacin, provide excellent coverage, including atypicals, according to the British Thoracic Society 4

Treatment should continue for a minimum of 5 days and until the patient has been afebrile for 48-72 hours with no more than one sign of clinical instability, as recommended by the British Thoracic Society 1
For most cases, 7-10 days of therapy is appropriate, and extended treatment to 14 days may be necessary for severe cases or specific pathogens like Staphylococcus aureus or gram-negative bacilli, according to the Infectious Diseases Society of America 3, 4
Clinical reassessment should occur at 48 hours or earlier if clinically indicated, and monitor temperature, respiratory rate, pulse, blood pressure, mental status, and oxygen saturation at least twice daily, as stated by the British Thoracic Society 1, 2

If MRSA is suspected, add vancomycin or linezolid to the regimen, and if Pseudomonas aeruginosa is a concern, use an antipseudomonal beta-lactam plus ciprofloxacin or an aminoglycoside, according to the Infectious Diseases Society of America 3, 4

Clinical review should be arranged for all patients at approximately 6 weeks after treatment, and a follow-up chest radiograph should be obtained for patients with persistent symptoms, physical signs, or those at higher risk of underlying malignancy, as recommended by the British Thoracic Society 1, 2